ABSTRACT: Intervertebral disc (IVD) degeneration (DD) is associated with low back pain, the leading cause of disability worldwide. Damage-associated molecular patterns (DAMPs) that contribute to inflammation and trigger DD have not been well characterized. Extracellular high mobility group box-1 (HMGB1) protein has been implicated as a potent DAMP and pro-inflammatory stimulus in the immune system. In this study, we show that HMGB1 and IL-6 levels increase in patients with advanced DD in comparison to early DD. This study further tested the hypothesis that HMGB1 promotes inflammatory signaling driving DD in human nucleus pulposus (NP) cells and tissue. Immunofluorescence and western blot analysis confirmed the expression of HMGB1 and its extracellular release by NP cells under cell stress. Gene expression and protein quantification indicate that HMGB1 stimulates the expression IL-6 and MMP-1 in a dose-dependent manner. The contributions of toll-like receptor (TLR) À2, À4 and receptor for advanced glycation end products (RAGE) as receptors mediating HMGB1 signaling was examined using small molecule inhibitors. Inhibition of TLR-4 signaling, with TAK-242, completely abrogated HMGB1 induced IL-6 and MMP-1 expression, whereas inhibition of TLR-2, with Ovanillin, or RAGE, with FPS-ZM1, had mild inhibitory effects. HMGB1 stimulation activated NF-ĸB signaling while TAK-242 cotreatment abrogated it. Lastly, effects of HMGB1 on matrix deposition was evaluated in a 3D culture system of human NP cells. These results implicate HMGB1 as a potent DAMP that promotes inflammation in NP cells and degradation of NP tissues. TLR4-HMGB1 axis is a potential major pathway to alleviate disc inflammation and mitigate DD. ß
Low back pain (LBP) is the leading cause of disability and is associated with intervertebral disc (IVD) degeneration. Treating IVD degeneration (DD) early-on is crucial to arrest disease progression, and to promote repair and restoration of a functional disc. 1 DD is characterized by the degradation of the proteoglycan rich extracellular matrix (ECM), loss of glycosaminoglycans (GAGs), ECM fibrillation, and production of inflammatory cytokines. 2 Recent studies suggests that endogenous damage-associated molecular patterns (DAMPs) within the IVD, such as ECM fragments, hyaluronan or fibronectin can serve as primary mediators of disc catabolism and degeneration. 3 High mobility group box-1 (HMGB1) is a DNA binding protein. [4] [5] [6] In the immune system, HMGB1 also acts as a prototypical DAMP, where it is either actively or passively released from cells during tissue damage or microbial invasion. 4, 6 HMGB1 levels have been found to be increased in inflammatory joint diseases such as rheumatoid arthritis, osteoarthritis, and synovitis. [7] [8] [9] Released HMGB1 has been shown to promote pro-inflammatory signaling through increased expression of cytokines such as tumor necrosis factor (TNF)-a, interleukin IL-1b, IL-6, IL-8, macrophage inflammatory proteins. 10, 11 Furthermore, HMGB1 can induce expression of catabolic molecules such as matrix metalloproteases (MMPs), such as MMP-1, MMP-3, and MMP-9 responsible for the breakdown of the ECM. 12, 13 The continuous and sustained production of HMGB1 and its downstream pro-inflammatory and catabolic molecules can eventually lead to tissue damage.
HMGB1 mediated inflammatory signaling occurs through a number of potential receptors, including toll-like receptor (TLR)-4, 14-17 TLR-2, 15 and receptor for advanced glycation end products (RAGE). 18, 19 Stimulation of these receptors has been shown to activate NF-kB pathway, which triggers the production of pro-inflammatory cytokines, such as IL-6 and MMP-1. 4, 13, 16, 20 In IVD, an elevated IL-6 level decreases expression of ECM constituents, aggrecan and Collagen Type II, 2, 21 and is associated with the progression of DD 22 and with LBP associated with DD. 23 MMP-1 levels have also been shown to be elevated in lumbar DD patients. 24 Hence, assessing the expression of HMGB1, IL-6, and MMP-1 levels serves as an indicator of pro-inflammatory and disease state.
However, the role of HMGB1 in the IVD is unclear. A recent study has shown that HMGB1 levels were elevated in severely degenerated and herniated human discs in comparison to less degenerated discs. 25 However there is no consensus on the pro-inflammatory effects of HMGB1 on disc cells. Klawitter et al. found that HMGB1 stimulation of disc cells isolated from patient samples resulted in inhibition of IL-6 but had no appreciative effect on IL-8 expression. 26 Whereas, Fang et al. found that stimulation of human annulus fibrosis (AF) cells with HMGB1-induced pro-inflammatory and catabolic cytokines such as prostaglandin E2 (PGE2), TNF-a, IL-1, IL-6, MMP-1,-3, and -9. 27 In AF cells, HMGB1 also increased TLR-4 and RAGE gene expression, and knock down of TLR-4 reduced proinflammatory effects of HMGB1. 27 Despite these findings, the effects of HMGB1 and the potential contributions of RAGE and TLR-2 relative to contributions of TLR-4 in nucleus pulposus (NP) cells are not known.
The goal of this study is to investigate the potential of HMGB1 to act as a DAMP in human NP cells and tissue-like constructs. To do this, we evaluated the translocation and release of HMGB1 and its proinflammatory effect under cell stress in human NP cells. We hypothesize that upon stress stimulation; HMGB1 will get translocated from the nucleus to cytoplasm and released extracellularly. Moreover, we investigated the effect of HMGB1 on stimulating proinflammatory and catabolic factors in human NP cells and matrix production within NP tissue-like constructs. We evaluated the contributions of key receptors responsible for HMGB1-induced pro-inflammatory signaling and the efficacy of inhibiting receptor signaling using small molecule inhibitors to confer protection against inflammatory factors in human NP cells. The mechanistic in vitro studies were also extended to evaluate the relationship between HMGB1 and DD severity in patient disc samples.
MATERIALS AND METHODS
Patient Disc Tissue Collection IRB approval was obtained prior to obtaining patient tissue samples for this basis science study. IVD tissue was obtained from 17 patients undergoing spinal surgery for symptomatic DD, disc herniation, or spinal stenosis. Disc tissues were snap frozen at the time of collection, and later processed for RNA using TRIspin method. Patient MRIs of the isolated disc level was evaluated and DD was classified using Pfirrmann grade, 28 and grouped into three subsets: "early" (Grade I & II), "intermediate" (Grade III), and "advanced" (Grade IV & V). HMGB1 and IL-6 mRNA levels were normalized to GAPDH, and fold change is reported relative levels measured in the "early" degeneration group.
Cell Culture Human NP cells were procured (CDD-H-2710-NP, Articular Engineering, Northbrook, IL) from lumbar spine of three healthy male donors (ages between 26 and 59 y) and cultured in complete media (DMEM/F12 þ 10% FBS þ 1% antibiotic/ antimycotic). Cells from each donor were expanded (P2-4) to generate sufficient cell numbers. Expanded cells, which have a propensity to de-differentiate during the expansion process, were confirmed to retain expression of aggrecan, an NP ECM marker.
Treatment of Cells With LPS or HMGB1
Human NP cells were treated with LPS (1 mg/ml, Escherichia coli: 0111:B4, Sigma-Aldrich, St. Louis, MO) for 16 h. Recombinant disulfide-HMGB1 was generously provided by lab of Dr. Kevin Tracey. 10, 29, 30 HMGB1 protein preparations were checked for potential endotoxin contamination using the Limulus Amebocyte Lysate assay (Lonza, Basel, Switzerland), and were found to be <0.01 EU/mg. Human NP cells were plated at a cell density of 5 Â 10 4 cells/cm 2 overnight. Cells were rinsed in PBS and incubated with HMGB1 (0, 0.5, 1, and 2 mg/ml) in complete media. After 24 h, cell medium supernatant was collected and cells were lysed for RNA isolation.
Ligand-Receptor Signaling Inhibition Using Small Molecule Inhibitors
This study evaluated three small molecule inhibitors for their ability to mitigate pro-inflammatory signaling by HMGB1 in human NP cells. [31] [32] [33] Following manufacturer's instructions, TAK-242 (Resatorvid, EMD Millipore, Billerica, MA), a TLR4 inhibitor (TLR4i) was dissolved in DMF (Thermo-Fisher Scientific, Grand Island, NY). O-vanillin (Sigma-Aldrich), a TLR2 inhibitor (TLR2i) and FPS-ZM1 (EMD Millipore), a RAGE inhibitor (RAGEi) were dissolved in DMSO (Fisher Scientific).
To confirm the specificity and compare effectiveness of the TLR4 and TLR2 inhibitors, their inhibitory effects were evaluated against stimulation with the best studied ligands of TLR4 and TLR2, LPS and PAM3CSK4, respectively. Human NP cells were pre-treated with different doses of TLR2i or TLR4i for 1 h, followed by co-treatment with either 1 ug/ml LPS or 0.1 ug/ml PAM3CSK4 in complete media for 24 h. For TAK-242, the doses tested were 0.1, 1, and 10 mM. For O-vanillin, the doses tested were 10, 100, and 1,000 mM. After 24 h, cells were used for gene expression analysis, and supernatant was used for cytotoxicity assessment.
To identify the effective dose of each small molecule inhibitor against HMGB1, human NP cells were plated and pre-treated with different doses of inhibitors for 1 h, followed by co-treatment with 2 mg/ml recombinant HMGB1 for 24 h. For TAK-242, the doses tested were 0.1, 1, and 10 mM. For Ovanillin, the doses tested were 10, 50, and 100 mM. For FPS-ZM1, the doses tested were 5, 10, and 100 mM. These doses of inhibitors tested were based on their respective IC 50 value in the literuare. [31] [32] [33] Inhibitor dose responses were compared to no-inhibitor group (Dose 0) which included HMGB1 treatment and the respective inhibitor vehicle (DMF or DMSO). RNA was harvested from the cells for gene expression analysis and the cell medium supernatant was collected for cytokine release and cytotoxicity analysis.
Based on the dose inhibitory responses, biological variability to these inhibitors were evaluated in cells from three donors. NP cells form each donor (n ¼ 3) were treated with a single dose of TAK-242 (1 mM), O-vanillin (100 mM) or FPS-ZM1 (10 mM) and compared to No-Inhibitor (HMGB1 treatment alone) and untreated group. Pre-treatment and cotreatment protocols used were same as described above. After 24 h, cells were lysed to harvest RNA and the medium supernatant was collected and frozen until further analysis.
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Inhibitor Combination Treatment by Blocking Multiple Receptors To determine if there are additive effects of blocking multiple receptors from HMGB1-induced signaling, NP cells were treated with TAK-242 (TLR4i, 1 mM), O-vanillin (TLR2i, 100 mM), or FPS-ZM1 (RAGEi, 10 mM) alone or in all other possible combinations (TLR4i þ TLR2i, TLR4i þ RAGEi, TLR2i þ RAGEi, TLR4i þ TLR2i þ RAGEi) following the pretreatment and co-treatment protocols described above. After 24 h, cells were lysed to harvest RNA and the medium supernatant was collected and frozen until further analysis.
3D Culture
In some experiments, human NP cells were cultured in a 3D cultures to maintain phenotype. Cells were suspended in alginate (1.2% alginate þ 150 mM NaCl þ 10 mM HEPES) at density of 3.3 Â 10 4 cells/bead and cultured in complete DMEM/F12 media for 5 weeks to promote ECM deposition. Alginate beads were treated with either 2 mg/ml HMGB1 AE 1 mM TAK-242 for 2 weeks. Beads were fixed, paraffin embedded, section and stained for histological analysis (Alcian blue-GAG staining, Picrosirius red-collagen staining, and H&E-cell morphology).
Immunofluorescence Staining
Following treatment with LPS or control media, cells were washed, fixed, permeabilized, and incubated with primary HMGB1 antibody (ab18256, Abcam, Cambridge, MA) at 2 mg/ ml overnight, followed by incubation with secondary goat anti-mouse Alexa Fluor 488 (Li-cor Biosciences, Lincoln, NE). Nuclei were stained with DAPI (Sigma-Aldrich). Images were obtained using the Leica DMI4000B fluorescence microscope (Leica Microsystems Inc., Buffalo Grove, IL) and LASX imaging software.
Image Analysis
To quantify HMGB1 nuclear-to-cytosolic ratio, binary masks were generated using Otsu's intensity-based thresholding (ImageJ, NIH). The nuclear region was identified from the DAPI stained images, and the corresponding HMGB1 stained images were thresholded to generate cytosol-only masks. HMGB1 signal levels were quantified in either the nucleus or cytosolic regions as integrated pixel intensity, and nuclear-to-cytosolic ratio was calculated and normalized to the corresponding areas of each region, as follows:
HMGB1 nuc=cyt ratio ¼ Nuclear HMGB1 signal=Area of nucleus Cytosolic HMGB1 signal=Area of cytosol
Western Blot Analysis
Cells were cultured in untreated or LPS treated conditions as described above in the section Cell Culture, and the supernatant cell medium was concentrated using Amicon Ultra-4 centrifugal filters (EMD Millipore). Protein concentration was measured using Pierce BCA Protein assay (Thermo-Fisher Scientific). Twenty m protein was denatured and separated on a 4-12% NuPAGE Novex Bis-Tris gel (Thermo-Fisher Scientific), followed by transferring onto a PVDF membrane (Biorad, Hercules, CA). The membrane was blocked and immunoblotted overnight with HMGB1 primary antibody at a concentration of 0.4 mg/ml at 4˚C and secondary Alexa Flour 680 goat anti-mouse IgG (Li-cor Biosciences) for 2 h at room temperature and visualized using Odyssey Infrared Imager (Li-cor Biosciences). Densitometric analysis of the bands was performed using Li-cor Image Studio 4.0 software.
NF-kB Activation
Phosphorylated-NF-kB levels were evaluated using western blot analysis. Cells were cultured in 1% FBS media for 24 h prior to treatment. Cells were then stimulated with either HMGB1 or HMGB1 þ TAK-242, as described above (see Inhibitor section). Following 10, 30, or 60 min, cells were lysed and the nuclear fraction was collected (NE-PER nuclear and cytoplasmic extraction kit, Thermo-Fisher Scientific). Protein lysates were run through 8% Tris-glycine SDSPolyacrylamide gels and transferred to nitrocellulose before blocking and staining. Blots were stained with phospho-NFkB-p65 rabbit monoclonal antibody (p-NFkb, Cell Signaling Technology, Danvers, MA) or lamin A/C (Cell Signaling Technology), sequentially. Anti-rabbit IgG HRP-linked secondary antibody (Cell Signaling Technology) was used, and blots were imaged using chemiluminescent detection (Azure c600, Azure Biosystems, Dublin, CA).
Gene Expression Analysis
Total RNA from each group (n ¼ 3 per group) was extracted using the RNEasy kit (Qiagen, Valencia, CA). RNA was quantified using Nanodrop (Thermo-Fisher Scientific) and amplification reactions were performed using One
Step Reverse Transcriptase qPCR MasterMix Plus (Eurogentec, Fremont, CA) and 7900 HT Fast Real-Time PCR System (Thermo-Fisher Scientific). Human Taqman primers for HMGB1 (Hs01923466_g1), interleukin-6 (IL-6, Hs00985639_m1), matrix metalloproteinase 1 (MMP-1, Hs00899658_m1) and housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Hs02758991_g1) were commercially purchased (Thermo-Fisher Scientific). Fold changes in the gene expression are reported using the 2 ÀDDCt method relative to respective untreated groups.
Cytokine Release Analysis IL-6 and MMP-1 levels in the medium supernatant were measured by human IL-6 DuoSet kit (R&D Systems, Minneapolis, MN) and Fluorokine E Human Active MMP-1 kit (APMA activated, R&D Systems) respectively, following the manufacturer's protocol.
LDH Cytotoxicity Assay LDH levels released from damaged or dying cells into the medium supernatant was measured using Cytotoxicity Detection kit (Sigma-Aldrich) following the manufacturer's protocol. The LDH levels were normalized to a positive control group, treated with 10% Triton X-100 to lyse all cells.
Statistics
Gene expression and ELISA data for IL-6 and MMP-1 are reported as the mean AE standard deviation (SD). For gene expression as a function degeneration severity, a one-way ANOVA was used with degeneration group as an independent variable. For analyzing effect of HMGB1 dose stimulation and inhibitor combinations, we performed a 2-way ANOVA with donor and treatment as variables. In all analyses, donor variability was not a significant contributor (p > 0.05). Therefore, subsequent HMGB1 and inhibitor dose 222 SHAH ET AL. treatment are presented based on one-way ANOVA, with dose as an independent variable, and Tukey HSD post-hoc test was used for pairwise comparisons. For the combination inhibitor experiment, multi-way ANOVA with a Tukey HSD post-hoc test was used, with TLR4i, TLR2i, and RAGEi as independent variables. All analyses were performed using STATISTICA (TIBCO Software, Palo Alto, CA). HMGB1 nuc/ cyt ratio was assessed on at least n ¼ 10 cells per group using an unpaired, two-tailed Student's t-test (GraphPad Software, La Jolla, CA). For all tests, p < 0.05 was considered significant.
RESULTS
Differential Expression of HMGB1 and IL-6 in IVD Biopsies From Patients With Different Grades of DD Expression levels of HMGB1 and IL-6 significantly increased with degeneration severity. Expression levels of HMGB1 with "advanced" degeneration grade were 2.25-fold greater compared to "early" degeneration grades (p < 0.022, Fig. 1A ). IL-6 levels were 12-fold greater in "advanced" group compared to "early" group (p < 0.021, Fig. 1B) . Levels of HMGB1 and IL-6 in the moderate degeneration group were slightly greater than the "early" group; however, these differences were not statistically significant.
HMGB1 Expression and Localization in Human NP Cells
In healthy human NP cells, we found basal expression of HMGB1 localized both to the nucleus and cytoplasm ( Fig. 2A) . Cell stress due to LPS stimulation resulted in nuclear emptying and robust cytoplasmic accumulation of HMGB1 ( Fig. 2A) . Fluorescence images were analyzed to quantify HMGB1 nuc/cyt ratio to compare HMGB1 translocation under control and cell stress conditions. HMGB1 nuc/cyt ratio was significantly reduced upon LPS treatment in comparison to untreated group (p ¼ 0.0124, Fig 2B) . LPS stimulation further resulted in extracellular release of HMGB1 as confirmed by western blot analysis of the cell medium supernatant (Fig. 2C) . Densitometry analysis shows that LPS stimulation promotes higher (>6-fold) extracellular secretion of HMGB1 compared to untreated cells after 24 h treatment (Fig. 2D) .
HMGB1 Promotes Pro-Inflammatory Signaling Molecules in a Dose-Dependent Manner
In considering the temporal gene expression response of human NP cells stimulated with HMGB1, we found the expression level at 12 and 24 h to be significantly greater than at 6 h (p < 0.02). The peak IL-6 response occurred between 12 and 24 h, with no significant difference between those two time points (p ¼ 0.36). In evaluating dose effects, HMGB1 treatment for 24 h significantly increased IL-6 and MMP-1 gene expression (Fig. 3A and D) in a dose-dependent manner (IL-6, 7.9-fold change in 2 mg/ml HMGB1 vs. Untreated, p < 0.0001; MMP-1, 6.7-fold change in 2 mg/ml HMGB1vs. Untreated), p < 0.0001). Protein levels of IL-6 and MMP-1 ( Fig. 3B and E) Fig. 3C ) and MMP-1 levels (r ¼ 0.877737, p < 0.0005, Fig. 3F ).
Effect of Blocking TLR-4, TLR-2, and RAGE on IL-6 Expression To confirm the specificity of TLR4i and TLR2i in the presence of known agonists, we measured IL-6 gene expression in cells co-treated with LPS AE TLR4i or in PAM3CSK4 AE TLR2i. We observed that both TLR4i and TLR2i significantly inhibited IL-6 expression in a dose dependent manner. (Fig. S1 A and C) . The concentration of inhibitor where the response is reduced by half (IC50) for TLR4i was 0.57 mM, and for TLR2i was 60.3 mM. Next, we evaluated the effect of blocking HMGB1-induced IL-6 expression. Results show that blocking of human NP cells with TLR4i significantly reduced HMGB1-induced IL-6 gene expression (p < 0.0006, Fig. 4A ) and its protein release (p < 0.0001, Fig. 4B ). Levels measured in 10 mM TLR4i were comparable with the untreated group (dotted line). We observed up to $50% inhibition of gene expression at an intermediate and high dose of TLR4i tested, whereas, inhibition at protein level was greater ($80%) relative to Dose 0 group. Blocking of NP cells with TLR2i resulted in 54% reduction of IL-6 gene expression at the highest dose (Fig. 4C) . Protein expression was reduced by 33% (Fig. 4D) . A partial but significant reduction was observed in gene expression at 100 mM TLR2i and at 50 and 100 mM doses for protein levels. Blocking of NP cells with RAGEi resulted in a mild reduction of IL-6 gene ( Fig. 4E ) and protein levels (Fig. 4F) . Reduction in gene expression was seen at 10 mM RAGEi dose whereas protein levels were lower both at 10 and 100 mM RAGEi doses. In all dose groups of RAGEi, the levels of IL-6 continued to be greater than that measured in untreated group (p < 0.0001).
Effect of Blocking TLR-4, TLR-2, and RAGE on MMP-1 Expression
Next, we tested the effect of blocking TLR-4, TLR-2, or RAGE signaling on MMP-1 expression. Similar to IL-6 inhibition, we verified the specificity of TLR4i and TLR2i to inhibit MMP-1 expression, in the presence of known agonists. We observed that both TLR4i and TLR2i significantly inhibited MMP-1 expression in the presence of LPS (TLR4 agonist) and P3C (TLR2 agonist), respectively ( Fig. S1 B and D) . Next, we evaluated the effect of blocking HMGB1-induced MMP-1 expression. Results show that blocking of NP cells with TLR4i significantly reduced HMGB1-induced MMP-1 gene expression (p ¼ 0.0014, Fig. 5A ) and MMP-1 protein levels (p < 0.0001, Fig. 5B ). Levels measured in 10 mM TLR4i were comparable to the untreated group (dotted line). Blocking of NP cells with TLR2i resulted in a partial reduction of MMP-1 gene expression (Fig. 5D ). MMP-1 protein levels were reduced by $34% (Fig. 5E) . Levels measured in 100 mM TLR2i remained significantly higher in untreated group. Blocking of NP cells with RAGEi resulted in no significant inhibition of MMP-1 gene expression or protein level ( Fig. 5G and H) . No significant cytotoxic effects were observed with any of the tested doses of TLR4i (Fig. 5C ), TLR2i (Fig. 5F ), or RAGEi (Fig. 5I ) in comparison to Dose 0 group. To compare the relative contributions of TLR-4, TLR-2, and RAGE signaling to effects of HMGB1 stimulation, we compared the most effective dose of each inhibitor. Results show that the RAGEi did not have a significant effect on IL-6 gene expression (Fig. 6A) or protein levels (Fig. 6B ). TLR2i induced a $52% reduction in IL-6 gene expression (p < 0.0002) and $49% reduction in IL-6 protein levels (p ¼ 0.01196). IL-6 gene expression levels in TLR2i group were significantly lower than RAGEi group (p < 0.0002). Moreover, TLR4i inhibited IL-6 gene and protein expression by >75% (p < 0.0002) and >90% (p < 0.0002) respectively. IL-6 gene expression in TLR4i group was significantly lower than observed with the RAGEi or TLR2i groups, nearing levels measured in untreated cells. Similar effects of the inhibitors were observed when evaluating MMP-1 gene and protein expression (Fig. 6C and D) .
Combinatorial Effects of Blocking TLR4, TLR2, and RAGE Signaling To evaluate potential additive contributions of multiple receptors to HMGB1-mediated signaling, the effect of each inhibitor alone was compared to all potential combinations of inhibitors. Expression of IL-6 and MMP-1 in TLR4i þ TLR2i or in TLR4i þ RAGEi groups were slightly lower than TLR4i alone, however this additive effect was not statistically significant (IL-6: p ¼ 0.77 and p ¼ 0.092, respectively. MMP1: p ¼ 0.99 and p ¼ 0.10, respectively). This suggests that the addition of TLR2i or RAGEi to TLR4i treatment did not have a significant additional effect (Fig. 7A) . However, IL-6 and MMP-1 levels in TLR4i þ TLR2i and TLR4i þ RAGEi groups were significantly lower than TLR2i alone (MMP1: p < 0.03) or RAGEi alone (MMP1: p < 0.0002), respectively. Interestingly, combining TLR4i þ TLR2i þ RAGEi resulted in inhibition of IL-6 that was comparable to TLR4i alone (p ¼ 0.11), but was significantly lower than TLR2i (p < 0.002) and RAGEi alone (p < 0.005) (Fig. 7A ). For MMP-1 expression, TLR4i þ TLR2i þ RAGEi group had similar expression to TLR4i alone (p ¼ 1.0), but it was lower than RAGEi alone (p < 0.005) (Fig. 7B) .
Effect of Blocking TLR-4 on NF-ĸB Activity
We tested the effect of HMGB1 AE TLR4i on levels of phosphorylated-NFĸB. Nuclear fraction levels of p-NFĸB increased at 30 and 60 min after stimulation of HMGB1 relative to untreated group. Co-treatment with TLR4i decreased p-NFĸB levels following 60 min of treatment (Fig. 8) . No major changes were observed in total NF-ĸB expression, or in the cellular fraction following treatment with HMGB1 or HMGB1 þTLR4i (not shown).
HMGB1 Induces ECM Degradation in a 3D Culture System Through TLR-4 Evaluation of ECM changes after 2 weeks of HMGB1 treatment in 3D cultured human NP cells revealed a reduced staining for GAGs (Alcian Blue) in the HMGB1 treated beads when compared to untreated (Fig. 9) . Co-treatment of 3D beads with TLR4i protected against the loss of GAG staining, keeping GAG levels similar to that observed in untreated samples (Fig. 9) . No significant change in collagen staining or cell morphology was observed in HMGB1 or HMGB1 and TLR4i treated samples, compared to untreated (Fig. 9 ).
DISCUSSION
The goal of this study was to evaluate the role of HMGB1 as a DAMP in human NP cells. Our findings demonstrate that HMGB1 and IL-6 expression increase with increasing degeneration severity in patient samples. HMGB1 is constitutively expressed by healthy human NP cells. In response to cell stress, HMGB1 gets translocated from nucleus to cytoplasm, and then released extracellularly. Mechanistically, exogenous HMGB1 stimulation of NP cells activates NF-ĸB signaling and promotes gene and protein production of IL-6 and MMP-1 in a dose-dependent manner. When blocking potential receptors of 
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HMGB1, we find that treatment of NP cells with the TLR4i, TAK-242, completely mitigated HMGB1-induced levels of IL-6 and MMP-1, and inhibited NF-ĸB activity. Additive effects of adding the TLR2i, OVanillin, or the RAGEi, FPS-ZM1, to TLR4i did not result in additional appreciable inhibition of IL-6 or MMP-1. In 3D cultures, HMGB1 promoted ECM degradation (GAG loss) which was mitigated with cotreatment with TLR4i. These findings suggest that disulfide-HMGB1 acts as a DAMP in human NP cells and its pro-inflammatory and ECM degradation activity is mediated primarily by TLR-4, which is inhibited with the intracellular small molecule inhibitor, TAK-242. The findings are graphically summarized in Figure 10 .
The findings of the current study are consistent with a study published by Fang et al., in human AF cells, however their study saw moderate pro-inflammatory effects upon HMGB1 stimulation, and more profound effects upon additive treatment with IL-1b. 27 This differential response could be due to cell type differences (AF vs. NP), or use of different HMGB1 redox forms. 29 In situ modulation of HMGB1 activity can change the redox form of HMGB1, and may favor the less pro-inflammatory state (e.g., oxidized-HMGB1 vs. disulfide-HMGB1). 29 Our findings however are not in agreement with that of Klawitter et al., who found that HMGB1 treatment inhibited IL-6 expression in human disc cells. 26 Our study evaluated effect of HMGB1 on "healthy" human NP cells, whereas Klawitter et al. evaluated disc cells isolated from degenerated (grade III-IV) patient tissues and hence the possibility that heterogeneous disease states may contribute to the measured responses.
Disulfide-HMGB1 interacts with multiple cell surface receptors to promote cytokine release from cells. We selectively targeted TLR-2, -4, and RAGE, with small molecule inhibitors that have been shown to block signaling through the respective receptors. We and others have previously confirmed the presence of these receptors in human NP cells. 26, 34, 35 Treatment of human NP cells with TLR4i completely mitigated Figure 9 . HMGB1 promoted GAG loss in 3D cultured human NP cells, while co-treatment with TLR4i inhibited GAG loss. Human NP cells were cultured in 3D for 5 weeks for mature ECM deposition to develop. Beads were then cultured for an additional 2 weeks either untreated or cotreated with 2 mg/ml HMGB1 AE 1 mM TLR4i. Staining included alcian blue (GAG staining), picrosirius red (collagen staining), and H&E (cell morphology). HMGB1-induced levels of IL-6 and MMP-1. Similar effects have been observed in epithelial cells, 14 macrophages, 6, 15, 29, 30 adipocytes, 20 and chondrocytes 17 . We saw a partial (33%) and modest (<11.6%) inhibition in protein levels of pro-inflammatory mediators with TLR-2i and RAGEi, respectively. These results indicate that TLR-2 and RAGE might play a smaller contributory role than TLR-4 in mediating HMGB1 signaling in human NP cells, and such conclusion is based on the specific activity of the small molecule inhibitor drugs used. Consistently, co-treatment of human NP cells with a combination of inhibitors of all three receptors had no additional effect on inflammatory signaling compared to treatment with TLR4i alone. We further tested the potential of the TLR4 and TLR2 antagonists to act in the presence of their respective agonists (Fig. S1) . We observed that both TLR4i and TLR2i were potent enough to downregulate IL-6 and MMP-1 expression in the presence of LPS (TLR4 agonist) and P3C (TLR2 agonist), down to untreated levels. However, similar inhibitory effects of TLR2i were not observed when HMGB1 is used as the stimulant.
We speculate that the activity and magnitude of HMGB1-triggered cytokine production in NP cells could be due to the physiochemical interactions that may occur due to the preferential high-binding affinity of HMGB1 to TLR-4. 6, 29 Furthermore, this effect might be further amplified by upregulation of TLR-4 receptor expression in pro-inflammatory environments. 26, 27, 36, 37 Hence, blocking of TLR-4 with the small molecule inhibitor TAK-242 may serve as a potential therapeutic pathway for mitigating HMGB1-induced signaling in NP cells.
Our findings that HMGB1 gene expression increases with DD is supported by a study by Gruber et al., where HMGB1 gene expression levels were increased in more degenerated (Thompson grade V) discs compared to less degenerated (grade I/II) discs and in herniated surgical specimens compared to control discs. 25 We have previously shown that rat discs injected with LPS, induces moderate DD and increased HMGB1 levels. 38 These findings further strengthen the association between disease state, HMGB1 expression, and pro-inflammatory signaling in IVDs. [39] [40] [41] [42] [43] [44] In response to pain-related behavior induced by the application of NP onto dorsal root ganglion (DRG) in vivo, administration of anti-HMGB1 neutralization antibody significantly improved animal's pain-associated behavior, suggesting HMGB1 blocking may be efficacious at treatment of pain due to disc herniation. 45 Together, these data implicate HMGB1 as a potential therapeutic target in treating disc herniation or DD to interrupt HMGB1-mediated disc injury.
Limitations of this study include the use of 2D expansion and culture, which can de-differentiate NP cells. Nevertheless, when human NP cells were cultured in 3D, we observed re-differentiation (GAG staining), and consistent findings regarding effects of HMGB1 and TLR4i. 2D expansion may also alter expression of TLRs, however a previous study found that TLR2 and TLR4 expression were similar in expanded human IVD cells. 24 Future studies will evaluate responses using disc organ cultures or in vivo.
CONCLUSION
The current study, for the first time, establishes HMGB1 as a DAMP in healthy human NP cells and NP tissue-like constructs. The present study indicates HMGB1 translocation and extracellular release as an upstream process can promote downstream inflammatory signals of NF-ĸB, IL-6, and MMP-1 via TLR-4 signaling in human NP cells. Blockade of TLR-4, with TAK-242, may provide an attractive approach for protection of human NP cells from long term injurious effects of HMGB1.
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